BioArctic

As of May 30, 2025, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,531,485 shares, of which 74,131,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,131,449.

---

This information is information that BioArctic is obliged to make public pursuant to the Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact persons below, on May 30, 2025, at 18:30 CET.

For further information, please contact:
Charlotte af Klercker, Senior Director Sustainability and Communications
Phone: +46 73 515 09 70
E-mail: charlotte.afklercker@bioarctic.com

Anders Martin-Löf, CFO 
Phone: +46 70 683 79 77
E-mail:  anders.martin-lof@bioarctic.com

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer’s disease, Parkinson’s disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company’s proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic’s B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.